Join Growin Stock Community!

杏國4192.TW Overview

TW StockBiotech. & Medical
(No presentation for 4192)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

杏國（4192）Overall Performance

杏國（4192）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

杏國（4192） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

杏國（4192）Key Information

杏國（4192）Profile

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and SB04,an conventional drug for the treatment of age-related macular degeneration that is in Phase II clinical trials. In addition, the company provides SB05-EndoTAG, an conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. The company has partnerships with Medigene AG and MacuCLEAR Inc.; Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes. SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.

杏國（4192）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
26.79
PB Ratio
2.73
Price-to-FCF
113.49
METRIC
VALUE
vs. INDUSTRY
Gross Margin
72.69%
Net Margin
-176.76%
Revenue Growth (YoY)
21.37%
Profit Growth (YoY)
955.06%
3-Year Revenue Growth
30.41%
3-Year Profit Growth
69.68%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
26.79
PB Ratio
2.73
Price-to-FCF
113.49
Gross Margin
72.69%
Net Margin
-176.76%
Revenue Growth (YoY)
21.37%
Profit Growth (YoY)
955.06%
3-Year Revenue Growth
30.41%
3-Year Profit Growth
69.68%
default symbol

4192

杏國

20.00D

-9.00%

(-0.09)

  • When is 4192's latest earnings report released?

    The most recent financial report for 杏國 (4192) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4192's short-term business performance and financial health. For the latest updates on 4192's earnings releases, visit this page regularly.

  • What is the operating profit of 4192?

    According to the latest financial report, 杏國 (4192) reported an Operating Profit of -8.75M with an Operating Margin of -135.23% this period, representing a growth of 38.52% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4192's revenue growth?

    In the latest financial report, 杏國 (4192) announced revenue of 6.47M, with a Year-Over-Year growth rate of 22.29%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4192 have?

    At the end of the period, 杏國 (4192) held Total Cash and Cash Equivalents of 171.28M, accounting for 0.63 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4192 go with three margins increasing?

    In the latest report, 杏國 (4192) did not achieve the “three margins increasing” benchmark, with a gross margin of 116.14%%, operating margin of -135.23%%, and net margin of -124.29%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4192's profit trajectory and future growth potential.

  • Is 4192's EPS continuing to grow?

    According to the past four quarterly reports, 杏國 (4192)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.23. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4192?

    杏國 (4192)'s Free Cash Flow (FCF) for the period is 439K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 71.93% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.